NEWRON PHARMACEUT. EO-20 (NP5) - Total Assets
Based on the latest financial reports, NEWRON PHARMACEUT. EO-20 (NP5) holds total assets worth €40.05 Million EUR (≈ $46.83 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NEWRON PHARMACEUT. EO-20 (NP5) net assets for net asset value and shareholders' equity analysis.
NEWRON PHARMACEUT. EO-20 - Total Assets Trend (2021–2025)
This chart illustrates how NEWRON PHARMACEUT. EO-20's total assets have evolved over time, based on quarterly financial data.
NEWRON PHARMACEUT. EO-20 - Asset Composition Analysis
Current Asset Composition (December 2025)
NEWRON PHARMACEUT. EO-20's total assets of €40.05 Million consist of 95.1% current assets and 4.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 30.4% |
| Accounts Receivable | €2.54 Million | 6.4% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how NEWRON PHARMACEUT. EO-20's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NEWRON PHARMACEUT. EO-20 (NP5) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NEWRON PHARMACEUT. EO-20's current assets represent 95.1% of total assets in 2025, an increase from 78.1% in 2021.
- Cash Position: Cash and equivalents constituted 30.4% of total assets in 2025, down from 49.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 6.4% of total assets.
NEWRON PHARMACEUT. EO-20 Competitors by Total Assets
Key competitors of NEWRON PHARMACEUT. EO-20 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $285.41 Million |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392
|
China | CN¥13.76 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
NEWRON PHARMACEUT. EO-20 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.76 | 2.60 | 3.73 |
| Quick Ratio | 0.76 | 2.60 | 3.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-12.05 Million | €37.60 Million | €14.70 Million |
NEWRON PHARMACEUT. EO-20 - Advanced Valuation Insights
This section examines the relationship between NEWRON PHARMACEUT. EO-20's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 193.81 |
| Latest Market Cap to Assets Ratio | 7.90 |
| Asset Growth Rate (YoY) | -37.3% |
| Total Assets | €40.05 Million |
| Market Capitalization | $316.25 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NEWRON PHARMACEUT. EO-20's assets at a significant premium (7.90x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: NEWRON PHARMACEUT. EO-20's assets decreased by 37.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for NEWRON PHARMACEUT. EO-20 (2021–2025)
The table below shows the annual total assets of NEWRON PHARMACEUT. EO-20 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €40.05 Million ≈ $46.83 Million |
-37.32% |
| 2024-12-31 | €63.91 Million ≈ $74.72 Million |
+147.07% |
| 2023-12-31 | €25.87 Million ≈ $30.24 Million |
-30.46% |
| 2022-12-31 | €37.20 Million ≈ $43.48 Million |
-26.33% |
| 2021-12-31 | €50.49 Million ≈ $59.02 Million |
-- |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more